Fusion Biopsy Market to Grow with a CAGR of 8.58% through 2029
Increase in the incidence of prostate cancer and
increase in the awareness and early detection is expected to drive the Global
Fusion Biopsy Market growth in the forecast period, 2025-2029
According to TechSci Research report, “Fusion
Biopsy Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2019-2029F”, the Global Fusion Biopsy Market stood at USD
570.01 million in 2023 and is anticipated to grow with a CAGR of 8.58% in the
forecast period, 2025-2029. The awareness among individuals regarding Fusion
Biopsy has led to favorable market conditions for the global Fusion Biopsy
market. Several factors contribute to the growth of various Fusion Biopsy
products. Fusion biopsy,
in contrast to traditional transrectal ultrasound-guided biopsies, is a less
invasive procedure, resulting in reduced risk of complications. In line with
the trend of patients seeking minimally invasive diagnostic and treatment
options, the appeal of fusion biopsies lies in the promise of minimized
discomfort, faster recovery periods, and decreased infection risk. These
advantages have fostered greater acceptance and adoption, thus contributing to
the continued growth of the market.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Fusion Biopsy Market”
Technological advancements in MRI and ultrasound
imaging have markedly enhanced the precision of fusion biopsies. The
utilization of high-resolution MRI and real-time ultrasound delivers intricate
prostate images, empowering healthcare professionals to pinpoint and target
suspicious lesions with heightened accuracy. With the ongoing evolution of
imaging technologies, fusion biopsy procedures gain increased effectiveness,
making them an appealing choice for both patients and healthcare providers,
which will further fuel market growth.
In September 2023, Eigen Health Ltd announces that it
has partnered with a leading global medical technology company to develop and
commercialize AI-powered solutions for the early detection of diseases in
emerging markets. The partnership is expected to accelerate the adoption of
Eigen Health Ltd's solutions in these markets and make them more accessible to
patients.
Public awareness initiatives and educational efforts
emphasizing the significance of early detection and prostate cancer screening
have resulted in a surge in the number of men actively seeking prostate cancer
diagnosis. Fusion biopsies, renowned for their capacity to identify cancer at
an earlier stage and deliver more precise diagnostic results, have garnered
increasing interest from both healthcare professionals and patients. Early
detection holds the potential to enhance treatment outcomes and survival rates,
rendering fusion biopsy an appealing choice.
In today's fast-paced world, Fusion biopsy combines
magnetic resonance imaging (MRI) and real-time ultrasound, enabling healthcare
professionals to swiftly identify and target suspicious areas within the body.
This efficiency accelerates the diagnostic process, reducing the time patients
need to spend on multiple diagnostic tests and consultations. In a fast-paced
world, time efficiency is of paramount importance, and fusion biopsy
streamlines the diagnostic journey. Fusion biopsy's precision and accuracy in
identifying specific lesions or abnormalities within the body is a critical
advantage. This ensures that patients receive a prompt and accurate diagnosis,
reducing the need for repeat testing or the risk of misdiagnosis. In a
fast-paced world, minimizing healthcare-related disruptions and achieving
swift, reliable results is highly valued. Fusion biopsy is less invasive
compared to traditional biopsy methods. Patients can often undergo the
procedure on an outpatient basis, with shorter recovery times. This is
advantageous for individuals with busy lifestyles, as they can return to their
daily routines more quickly, avoiding prolonged hospital stays and disruptions
to their schedules.
The growing prostate cancer ranks among the most
common malignancies affecting men globally. The growing occurrence of prostate
cancer cases, frequently identified in advanced stages, has stimulated the need
for highly accurate and minimally invasive diagnostic methods. Fusion biopsy,
renowned for its capacity to precisely pinpoint suspicious regions within the
prostate, presents a superior substitute for traditional biopsies, thereby
propelling market expansion.
In recent times, the ability to precisely target
suspicious areas within the body, Fusion Biopsy is a crucial tool for the early
detection of various cancers, especially prostate cancer. Early diagnosis
significantly improves treatment outcomes and survival rates. In an era when
healthcare is increasingly focused on prevention and early intervention, Fusion
Biopsy plays a pivotal role. Fusion Biopsy is less invasive than traditional
biopsy methods. This is particularly relevant in recent times when patients and
healthcare providers are seeking less traumatic and more patient-friendly
diagnostic procedures. The reduced pain and discomfort associated with Fusion
Biopsy enhance patient satisfaction and compliance with recommended diagnostic
tests. Fusion Biopsy combines advanced imaging technologies, such as MRI and
real-time ultrasound, to deliver highly precise and accurate results. In recent
times, there is a growing demand for diagnostic methods that minimize the risk
of misdiagnosis and ensure that patients receive the most appropriate treatment
quickly. Fusion Biopsy meets this demand effectively. However, the cost of
fusion biopsy procedures and equipment may hinder market growth. Moreover,
challenges related to Limited access to advanced medical infrastructure and
Competition from alternative diagnostic methods may pose obstacles to the
Fusion Biopsy market in the near future.
The Global Fusion Biopsy Market is segmented into
biopsy route, end-user, regional distribution, and company
The Transrectal biopsy route has long been established and widely utilized for diagnosing prostate cancer, enjoying a high level of familiarity among physicians and urologists. Its extensive historical usage makes it the preferred choice for many healthcare providers. This established prevalence provides the Transrectal segment with a notable advantage, as medical professionals typically adhere to methods they are comfortable with. Furthermore, Transrectal biopsy is easily accessible and can be conducted in various healthcare settings, including outpatient clinics and hospitals. This convenience renders it the preferred option for both patients and physicians. Additionally, when Fusion biopsy is performed transrectally, it seamlessly integrates into existing infrastructure and workflows, ensuring minimal disruption to established diagnostic procedures.
In the North American market segment, growth is anticipated throughout the forecast period. This is attributed to the region's highly developed healthcare infrastructure, characterized by an extensive network of hospitals, clinics, and diagnostic centers equipped with state-of-the-art medical technologies. Fusion biopsy, which necessitates advanced imaging equipment and specialized expertise, is readily accessible in this area. Prostate cancer poses a significant health challenge in North America, with a high incidence rate, thereby fueling the demand for precise and dependable diagnostic tools like fusion biopsy. Given the emphasis on early detection and treatment, fusion biopsy assumes a pivotal role in the region's healthcare landscape. North America boasts a substantial pool of skilled healthcare professionals, including urologists and radiologists, who are crucial for performing and interpreting fusion biopsy procedures accurately. The availability of specialized expertise contributes to the widespread adoption of fusion biopsy. Furthermore, the region leads in research and development within the medical technology sector.
The Fusion Biopsy sector stands to capitalize on
the burgeoning European market, which is poised to become the fastest-growing
segment in the foreseeable future. This growth trajectory is underpinned by
several factors, foremost among them being the escalating prevalence of
awareness campaigns and initiatives aimed at promoting early cancer detection
throughout Europe. Notably, there has been a marked increase in awareness and
screening programs for prostate cancer, leading to a surge in patient demand for
diagnostic services such as fusion biopsy. European nations, particularly those
boasting advanced healthcare systems, are making substantial investments in the
enhancement of their healthcare infrastructure. This includes the procurement
of state-of-the-art imaging equipment and the expansion of healthcare
facilities, thereby directly facilitating the growth of fusion biopsy services.
Mirroring trends observed in North America, Europe is experiencing a rise in
the incidence of prostate cancer, underscoring the urgent imperative for early
and accurate diagnosis. As a result, there is a burgeoning demand for fusion
biopsy as a dependable diagnostic tool. Moreover, European healthcare providers
are increasingly embracing cutting-edge medical technologies. Fusion biopsy,
renowned for its precision and non-invasive nature, aligns seamlessly with the
region's steadfast commitment to elevating patient care standards and improving
treatment outcomes.
Major companies operating in Global Fusion
Biopsy Market are:
- Eigen Health Ltd
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- MedCom Inc
- Esaoate SpA
- KOELIS SAS
- Focal Healthcare Inc
- UC-Care Medical Systems Ltd.
- GeoScan Medical
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The Advancements in Imaging Technologies and
increasing Minimally Invasive Procedures are key drivers of the Fusion Biopsy
market. In recent years, the growing Public health campaigns and educational
initiatives have increased awareness about the importance of early cancer
detection. Fusion biopsy, with its ability to detect cancer at an early stage,
plays a significant role in this effort. Moreover, the growing consumer
emphasis on preventative healthcare has enhanced production and marketing
efforts. To meet the demands of the market, manufacturers are increasingly
incorporating cutting-edge technologies with high production efficiency. Rising
consumer acceptance and continuous product innovation will further ensure the
growth of the Fusion Biopsy market in the coming years.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Fusion Biopsy Market – Global Industry Size, Share,
Trends, Opportunity, & Forecast, Segmented By Biopsy Route
(Transrectal, Transperineal), By End-User (Hospitals, Diagnostic Centers,
Ambulatory Care Centers), By Region, Competition, 2019-2029F”, has evaluated
the future growth potential of Global Fusion Biopsy Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Fusion Biopsy Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com